I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advance..:
Naing, Aung
;
Thistlethwaite, Fiona
;
Vries, Elisabeth G.E, de
...
Reproducció del document publicat a: https://doi.org/10.1136/jitc-2021-002447. , 2021
Link:
http://hdl.handle.net/2445/179966
RT Journal T1
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
UL https://suche.suub.uni-bremen.de/peid=base-ftubarcepubl:oai:diposit.ub.edu:2445_179966&Exemplar=1&LAN=DE A1 Naing, Aung A1 Thistlethwaite, Fiona A1 Vries, Elisabeth G.E, de A1 Eskens, Ferry A1 Uboha, Nataliya A1 Ott, Patrick A A1 Lorusso, Patricia A1 García Corbacho, Javier A1 Boni, Valentina A1 Bendell, Johanna A1 Autio, Karen A A1 Randhawa, Manreet A1 Durm, Greg A1 Gil Martin, Marta A1 Stroh, Mark A1 Hannah, Alison L A1 Arkenau, Hendrik-Tobias A1 Spira, Alexander PB BMJ YR 2021 K1 Farmacoimmunologia K1 Desenvolupament de medicaments K1 Immunopharmacology K1 Drug development JF Reproducció del document publicat a: https://doi.org/10.1136/jitc-2021-002447 LK http://hdl.handle.net/2445/179966 DO http://hdl.handle.net/2445/179966 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)